+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation



Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation



Mutagenesis 29(5): 341-350



Next generation sequencing has become a powerful tool in dissecting and identifying mutations and genomic structural variants that accompany tumourigenesis. Sequence analysis of glioblastoma multiforme (GBM) illustrates the ability to rapidly identify mutations that may affect phenotype. Approximately 50% of human GBMs overexpress epidermal growth factor receptor (EGFR) which renders the EGFR protein a compelling therapeutic target. In brain tumours, attempts to target EGFR as a cancer therapeutic, however, have achieved little or no benefit. The mechanisms that drive therapeutic resistance to EGFR inhibitors in brain tumours are not well defined, and drug resistance contributes to the deadly and aggressive nature of the disease. Whole genome sequencing of four primary GBMs revealed multiple pathways by which EGFR protein abundance becomes deregulated in these tumours and will guide the development of new strategies for treating EGFR overexpressing tumours. Each of the four tumours displayed a different mechanism leading to increased EGFR protein levels. One mechanism is mediated by gene amplification and tandem duplication of the kinase domain. A second involves an intragenic deletion that generates a constitutively active form of the protein. A third combines the loss of a gene which encodes a protein that regulates EGFR abundance as well as an miRNA that modulates EGFR expression. A fourth mechanism entails loss of an ubiquitin ligase docking site in the C-terminal part of the protein whose absence inhibits turnover of the receptor.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056941390

Download citation: RISBibTeXText

PMID: 25103728

DOI: 10.1093/mutage/geu026


Related references

Next generation sequencing and molecular imaging identify EGFR mutation and amplification in a glioblastoma multiforme patient treated with an EGFR inhibitor: a case report. Oncotarget 8(30): 50305-50313, 2017

Chromogenic in situ hybridization accurately identifies EGFR amplification in small cell glioblastoma multiforme, a common subtype of primary GBM. Clinical Neuropathology 24(4): 163-169, 2005

Whole-genome mRNA expression profiling identifies functional and prognostic signatures in patients with mesenchymal glioblastoma multiforme. Cns Neuroscience & Therapeutics 19(9): 714-720, 2014

Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma. Cancer Informatics 13(Suppl 2): 49-53, 2014

Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer 119(4): 814-824, 2013

Utilizing the Dog Genome in the Search for Novel Candidate Genes Involved in Glioma Development-Genome Wide Association Mapping followed by Targeted Massive Parallel Sequencing Identifies a Strongly Associated Locus. Plos Genetics 12(5): E1006000-E1006000, 2017

In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Molecular Cancer Research 10(3): 428-440, 2012

Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme. Journal of Neuro-Oncology 136(3): 463-474, 2017

Whole Genome Sequencing-Based Discovery of Structural Variants in Glioblastoma. Methods in Molecular Biology 1741: 1-29, 2019

Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. Neuro-Oncology 16(12): 1607-1617, 2015

Personalized genome sequencing coupled with iPSC technology identifies GTDC1 as a gene involved in neurodevelopmental disorders. Human Molecular Genetics 26(2): 367-382, 2017

Alteration in NFKBIA and EGFR in glioblastoma multiforme. Neurosurgery 68(6): N14-N15, 2011

Re: whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. European Urology 67(2): 350-351, 2015

Deep sequencing of Brachypodium small RNAs at the global genome level identifies microRNAs involved in cold stress response. Bmc Genomics 10: 449-449, 2009

EGFR overexpression and radiation response in glioblastoma multiforme. International Journal of Radiation Oncology Biology Physics 51(2): 410-418, October 1, 2001